key: cord-0936027-lphah7df
authors: Chung, Young Hun; Church, Derek; Koellhoffer, Edward C.; Osota, Elizabeth; Shukla, Sourabh; Rybicki, Edward P.; Pokorski, Jonathan K.; Steinmetz, Nicole F.
title: Integrating plant molecular farming and materials research for next-generation vaccines
date: 2021-12-06
journal: Nat Rev Mater
DOI: 10.1038/s41578-021-00399-5
sha: a0627ba0191f860ed928dfafc0a82507c2fceada
doc_id: 936027
cord_uid: lphah7df

Biologics — medications derived from a biological source — are increasingly used as pharmaceuticals, for example, as vaccines. Biologics are usually produced in bacterial, mammalian or insect cells. Alternatively, plant molecular farming, that is, the manufacture of biologics in plant cells, transgenic plants and algae, offers a cheaper and easily adaptable strategy for the production of biologics, in particular, in low-resource settings. In this Review, we discuss current vaccination challenges, such as cold chain requirements, and highlight how plant molecular farming in combination with advanced materials can be applied to address these challenges. The production of plant viruses and virus-based nanotechnologies in plants enables low-cost and regional fabrication of thermostable vaccines. We also highlight key new vaccine delivery technologies, including microneedle patches and material platforms for intranasal and oral delivery. Finally, we provide an outlook of future possibilities for plant molecular farming of next-generation vaccines and biologics.

A human analogue of insulin (Humulin) was the first biologic introduced into the market in 1983. Since then, biologics have been increasingly used as pharmaceutical agents, outpacing the market of small-molecule drugs 1 with an estimated market size of around US$400 billion by 2025 (ref. 2 ). Biologics are a class of medications that are derived from a biological source and typically fall into one of four major categories: monoclonal antibodies (mAbs), receptor modulators, enzyme modulators and vaccines 3 . Vaccines have been crucial in eliminating infectious diseases, such as smallpox 4 and rinderpest in 2011 (ref. 5 ), and in eradicating once-deadly diseases, such as diphtheria, measles, polio and rubella, by 99%, with many other diseases, such as mumps, pertussis and tetanus, nearing that stage. In the USA alone, it is estimated that in just one generation of children, 13 different vaccines have prevented up to 20 million diseases and 40,000 deaths, with economic savings of up to US$69 billion 4 . On a global scale, these numbers are much higher; one estimate shows that ten vaccines deployed in 94 low-and middle-income countries led to a US$586 billion reduction in illness-related costs, and a reduction of up to US$1.53 trillion when considering additional economic benefits 6 .

Vaccines are usually manufactured using cell-based expression systems, such as mammalian and insect cell lines, bacterial or yeast cultures. Plant molecular farming, that is, using plant cells or plants as expression platforms, is a rapidly emerging alternative, which was originally introduced in 1986 for the production of human growth hormone (HGH) in transgenic tobacco and sunflowers 7 . Plant molecular farming is currently used for the production of seasonal influenza vaccines 8 and for Elelyso for Gaucher disease in the USA 9 . Although plant molecular farming may not replace industrial expression systems, it may have a unique role in the generation of vaccines in low-resource areas, for targeting niche and orphan vaccines, and for the production of virus nanoparticles (VNPs) for vaccine applications 10 . Furthermore, the rise of the coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) has focused research attention on novel approaches to vaccines. Traditional vaccines are either live attenuated (that is, less virulent forms of the original pathogen), inactivated (that is, inactivated pathogen without disease-producing capacity), or recombinant proteins and viral vectors. In addition, the two vaccines that were first granted emergency authorization in the USA for COVID-19 are messenger RNA (mRNA) vaccines delivered in lipid nanoparticles 11 .

In this Review, we discuss challenges in current vaccine development and distribution, such as cold chain

Integrating plant molecular farming and materials research for next-generation vaccines allows the virus to escape antibody responses to targeted antigens 18 . High variability may be addressed by universal vaccines, which are effective against all virus subtypes and are impervious to future mutations by the pathogen. For example, the Gardasil-9 vaccine provides immunity against nine human papillomavirus (HPV) types, which should prevent >90% of HPV infections and subsequent cervical cancer 19 ; however, expanding immunity protection to all known HPVs would enable HPV eradication. A universal vaccine against influenza would also greatly decrease infection rates, health-care costs and associated mortality, while improving patient compliance 20 . Nanotechnology-based approaches, such as HPV-encapsidating microneedles 21 and slowrelease implant technologies 22 , could further improve immunization against these difficult pathogens.

Vaccines are also being developed for non-infectious pathophysiological conditions, such as autoimmune diseases and cancers 23 . These vaccines are difficult to produce, because the molecular causes and antigens are often specific to the individual patient. Therefore, unlike for infectious disease vaccines, here it may be more advantageous to produce patient-specific vaccines -a considerable challenge for conventional production methods. Improvements in biotechnology methods, such as whole-exome or RNA sequencing 24 , may allow the isolation of patient-specific antigens for the creation of specialized vaccines.

Nanotechnology-based approaches have also played a key part in the development of COVID-19 mRNA vaccines, although it remains to be seen whether mRNA vaccines will provide long-or short-lasting immunity against SARS-CoV-2. Furthermore, the lack of thermostability of lipid nanoparticle formulations requiring storage and distribution in ultralow-temperature freezers presents a great challenge for vaccine distribution to rural and low-resource regions because these vaccines are temperature-stable only when frozen at -20 to -80 °C. Viral vector vaccines may be better suited for vaccination in remote areas, because they can be stored at higher temperatures of up to 4 °C. However, early reports suggest that viral vector vaccines do not reduce symptomatic infection as well as mRNA vaccines 25 , although the differing trial protocols and demographics make it difficult to compare the trials equally.

Humulin, the first biologic used in humans 1 , is expressed in Escherichia coli 26 . Advances in DNA technology have further enabled vaccine production in yeast, for example, for the production of subunit vaccines against the hepatitis B virus (HBV) 27 . In addition, mammalian cells, insect cells and chicken eggs can be applied as expression systems for vaccine production.

Bacteria are the most widely used expression system, benefiting from low cost, rapid growth and ease of use; in ideal conditions, E. coli can double its biomass within 20 minutes 28 . An estimated 30% of all biopharmaceuticals are currently engineered in bacterial systems, with E. coli being the most widely used strain 29 . Bacterial systems are also applied to generate DNA plasmids, which are subsequently used to produce the final biologic.

The main disadvantage of bacterial systems is the lack of eukaryotic post-translational modifications. Without proper post-translational modification, purified proteins may behave differently in vivo 26 compared with their non-recombinant counterparts, which can lead to diminished or total loss of activity, reduced half-life and decreased stability and/or immunogenicity 30 . Moreover, the presence of rare codons in eukaryotic genes can be problematic, because they can cause early termination during bacterial protein production, necessitating the redesign of genes 31 .

To overcome the problems associated with bacterial protein production, mammalian cell lines can be used. From 2016 to 2018, 84% of pharmaceutical proteins were made in mammalian cell lines, predominantly in Chinese hamster ovary (CHO) cells 32 . CHO cells achieve high protein yield (up to 10 g l -1 for some proteins) 33 , they can grow in suspension 34 and they can withstand changes in external factors, such as temperature and pH 35 . However, although post-translational modifications in CHO cells more closely resemble those of human cells, they are not identical and can induce immune or other adverse reactions in patients 36 .

Alternatively, insect cells replicate faster than mammalian cells, enabling faster protein expression, but are more costly than bacteria owing to the requirement of specialized culture media 28 . A main disadvantage of insect cells is also the difference in post-translational modifications, as compared with human cells, which can make the biologics immunogenic 37 . Furthermore, some insects carry pathogenic viruses (for example, arboviruses) and, thus, insect cell lines must be closely examined before regulatory approval 38 . Furthermore, insect cells can produce proteases in response to viral transfection that can digest the protein of interest 37 .

Finally, chicken eggs are widely used for vaccine production, for example, for influenza vaccines 39 . Although well established, antigenic drift in chicken eggs can decrease vaccine efficacy, compared with vaccines produced in cell-based systems 40 . In addition, vaccine production in chicken eggs can take up to 6 months, whereas insect cell systems can produce vaccines in 39 . Possible contamination with human pathogens can also be a problem, which can be avoided by molecular farming 41 .

Since the production of HGH in transgenic tobacco 7 , many proof-of-concept and efficacy tests have been performed of plant-made therapeutics and vaccines for humans and animals 42 ( Table 2) . A tobacco-produced mAb used in the production of a hepatitis B subunit vaccine 43 and a Newcastle disease subunit vaccine for poultry made in cultured tobacco cells were the first plant-made recombinant proteins to receive regulatory approval in 2006 (ref. 44 ) ( fig. 1 ). However, only one human therapeutic (Elelyso, a mitochondrial enzyme deficit therapy for Gaucher disease) produced by molecular farming has thus far been licensed by the US Food and Drug Administration (FDA) 9 . In addition, the first phase III human clinical trial for a plant-produced vaccine has just been successfully concluded. This virus like particle (VLP)-based quadrivalent seasonal influenza virus vaccine is currently undergoing final consideration for licensure in Canada 8 . The fact that only a few plant-produced therapeutic products have been clinically translated thus far may be more related to industrial and regulatory inertia than to product inadequacy, especially given the plentiful evidence of functional equivalency. Transgenic plant and plant cell production of proteins laid the foundation of plant molecular farming; however, it was the advent of transient expression technologies that unleashed its true potential, including plant virus-derived vectors, somatic transformation of cells in normal plants (usually by infiltration of Nicotiana benthamiana with Agrobacterium suspensions), and hybrid methods involving delivery of replicating vectors by Agrobacterium 42 (box 1). These transient technologies enable protein expression within days of gene cloning, instead of relying on the generation of stable transgenic plants, which can take years. Moreover, yields are usually higher and more consistent, than transgenic plant systems, because these techniques do not depend on genome insertion sites and expression is not downregulated by methylation or other gene modifications, enabling much faster experimentation and optimization of expression. In addition, production scale-up is more efficient than transgenic plants and conventional cell-based technologies. Only a small volume of recombinant Agrobacterium suspension has to be grown for the biologic of interest, which can then be combined by agroinfiltration with as many plants -grown cheaply in nearby facilities -as required. It is striking that Medicago Inc. received funding from the US Defense Advanced Research Projects Agency (DARPA) Blue Angel initiative to produce ten million doses of current good manufacturing practice (cGMP)-level influenza vaccines 1 month after receiving the sequence of the virus 45 . Medicago Inc. has further announced preliminary success in investigating a VLP-based COVID-19 vaccine candidate, which was produced in just over 20 days after receiving the spike protein gene sequence 46 . Phase I clinical trial results showed ten times more production of neutralizing antibodies than in convalescent sera 47 . This vaccine candidate has recently entered phase II/III clinical trials and is administered along with GlaxoSmithKline's AS03 adjuvant 48 .

The microalga Chlamydomonas reinhardtii is the most commonly used algal system for molecular farming 49 and has been applied to express mAbs (against glycoprotein D of the herpes simplex virus and human fibronectin type III), subunit vaccines (viral protein (VP) 1 of foot-and-mouth disease), allergens (peanut allergens), growth factors (vascular endothelial growth factor), and immunotoxins (chimeric antibody to CD22 and exotoxin A) 50 . Although the genomes of the mitochondria, nucleus and chloroplast of C. reinhardtii have been sequenced 51 , expression has been mainly applied in chloroplasts thus far, because the chloroplast genome is small and simple 50 , and biologics can be sequestered in the chloroplast without harming the host cells or being degraded 51 . However, similar to bacterial expression, post-translational modifications are lacking in this system. Alternatively, Lemna and moss systems have been explored for biologic expression 52, 53 .

Using plants for vaccine production has the advantage that plants are cheaper than mammalian systems in terms of biomass production, and they have similar protein folding, assembly and glycosylation 54 . Therefore, plants can be applied to efficiently produce a range of pharmaceuticals at low cost. It is estimated that the final cost of producing biologics in plants is 68% of that in conventional production systems (site and batch costs are lower in plants, whereas downstream processing costs are identical) 55 . Furthermore, post-translational modifications, such as glycosylation, can be manipulated in plants. Thus, plant-produced products have appropriate glycan structures, which can improve half-lives of products and ease downstream processing 56 . For example, Elelyso is considered a 'biobetter' (biologics that improve upon existing biologics), compared with its CHO-produced counterpart, because the end product contains terminal mannose residues that aid in macrophage receptor binding 57 . In CHO cell production, mannose residues are attached in vitro, adding an extra step and increasing the costs 58 haemagglutinin proteins made in plants were shown not to induce problematic adverse effects in clinical trials despite non-mammalian glycosylation 59 . In proteins that require human glycosylation, such as the HIV-1 Env gp140 protein, the yield can be substantially increased and the glycosylation pattern of HIV-1 Env gp140 can be altered through coexpression of human chaperonins in N. benthamiana plants, engineered to not produce xylose or fucose transferases 60 . Plants and plant cells are also inherently safer than bacterial and mammalian systems owing to the low possibility of harmful contamination. In contrast to these systems, plants do not produce endotoxins and cannot be infected by pathogens harmful to humans 61 . Therefore, plants could potentially be used in edible vaccines 62 , although concerns of cross-contamination and accidental vaccination of wildlife have stalled development in this field.

Various vaccine candidates have already been produced by molecular farming, including HIV-1 Env 60 , ten different HPV L1 proteins 63 , West Nile virus envelope protein 64 and dengue virus VLPs 65 . Notably, this list includes three different envelope glycoproteins or their derivatives. In addition, a recombinant double-stranded DNA (dsDNA) molecule has been encapsidated in HPV-16 pseudovirions, which were made in plants 66 , proving that DNA vaccines and their delivery systems can be succesfully produced in plants. Similarly, mRNA vaccines can be produced in plants; for example, recombinant mRNA molecules can be expressed in plants from DNA vectors and specifically encapsidated by adding an assembly signal in tobacco mosaic virus (TMV) coat proteins. Synthetic mRNAs made in vitro can also be encapsidated with purified TMV coat proteins, which was first demonstrated in 1956 with TMV RNA 10 . Encapsulation of target and self-replicating mRNA can be achieved in plants through co-expression of the desired mRNA and the TMV coat proteins 67 , making this an attractive and scalable approach towards plant-produced mRNA vaccines.

The limited commercialization of plant cell culturebased expression systems may be related to the lower protein yield (usually 0.01-10 mg l -1 , although up to 247 mg l -1 have been reported) 68 , compared with bacterial and mammalian cell culture, which can achieve up to 10 g l -1 (ref. 33 ). Additionally, controlling the expression levels of certain proteins remains difficult, especially in transgenic plants. Expression can vary between different generations of plants, is highly dependent on the plant type, and can even fluctuate within the same plant's tissues and organs 42 . Plants may also suffer from variability of environmental conditions, such as droughts and extreme heat -although this is less problematic in growth houses.

Cookie technique. The cookie technique, that is, the transient transformation of plant cells to produce high-value proteins, may revolutionize the small-scale production of recombinant proteins and other biologics in cultured plant cells 69 . Here, cell packs or 'cookies' are made on porous supports by filtration of suspended cells, followed by incubation with Agrobacterium suspensions without resuspension. The bacteria are then washed out with growth medium, leaving behind a mass with many air spaces. The treatment results in transformation rates of up to 100%, compared with around 1% from co-incubation of cells with Agrobacterium in suspension 70 . Cell packs can be incubated for days in situ and can produce up to 47 mg kg -1 of recombinant protein.

The technique is scalable from microlitre and millilitre volumes up to large-volume preparative columns used for filtration or chromatography, and thus can be used for high-throughput and low-volume screening and for subsequent production of trial batches of proteins.

Patient-specific antigens. Although molecular farming may not displace fermentation and large-volume cell culture for the production of blockbuster vaccines and therapeutics, it may be advantageous in certain appli cations; for example, for patient-specific or individualized production of antigens for therapeutic vaccines, which are required for certain diseases, such as non-Hodgkin lymphoma 71 . mAbs can be produced with relative ease in plants and, thus, non-Hodgkin lymphoma was The solution is then conditioned for the purification process, which usually comprises a series of multistep chromatography methods. The order of chromatography depends on the biologic (for example, monoclonal antibodies are purified on protein A columns), but often ion exchange chromatography is followed by hydrophobic interaction chromatography. Alternatively, affinity chromatography can be applied: a substance that can bind the protein of interest is attached to a solid matrix (for example, antibodies or enzyme substrates) to pull the protein out of solution. Additional tags, which are recognized and bound, can be added to the N-or C-terminus of the protein to aid purification. These tags may, however, interfere with the biological activity of the protein. The tag can subsequently be removed by adding a protease cleavage site between the tag and the protein (for example, a thrombin cleavage site), although this requires an additional round of purification.

www.nature.com/natrevmats an early target for molecular farming 72 . Here, the mAbs are produced by introducing recombinant TMV (magnICON) vectors into N. benthamiana plants using Agrobacterium 73 . Grams of purified protein, enough for a lifetime supply for a patient, were produced at a cost of only about US$15,000 (2015); for comparison, production by conventional expression systems is estimated to cost around ten times more.

Niche and orphan diseases. Molecular farming also has potential for the production of niche or orphan vaccines as well as therapies, for which the market is perceived as too small to invest in a potential vaccine (for example, Lassa fever in West Africa), and/or the target market cannot afford the costs (for example, Rift Valley fever in East Africa). Importantly, such niche or orphan diseases have a role in the One Health Initiative, which aims to produce reagents for a disease that can infect wildlife, livestock or humans and to repurpose these into vaccines for animals or humans 74 . For example, the nucleoproteins of both Crimean-Congo haemorrhagic fever 75 and Rift Valley fever 76 bunyaviruses have been produced in plants with high yield and used in validated serological assays. In addition, SARS-CoV-2 spike glycoproteins have been made in plants in various forms for laboratories and detection kit manufacturers 77 .

Plant virusderived VNPs are best produced in their natural hosts, that is, plants, by infection or recombinant expression, yielding milligrams of VNPs or VLPs per gram of leaf tissue 10 . VLPs are the non-infectious version of VNPs and do not contain the viral genome. Plant VNPs are proteinaceous nanomaterials that self-assemble into precise geometries at the nanometre scale. Many of their coat proteins have been mapped to near-atomic resolution, allowing functionalization with spatial control; molecular payloads can be incorporated into the interior cavity, integrated at interfaces, or displayed at the surface using an array of chemical biology approaches 78 ( fig. 2a-c) . Thus, VNPs can be used as nanocarriers with a variety of payloads, including small-molecule drugs and prodrugs, nucleic acids, therapeutic proteins, contrast agents and photosensitizers for drug delivery 79 86 . Therefore, this technology is ideal for human vaccines and immunotherapies.

Although non-infectious to mammals, the repetitive, multivalent coat protein assemblies are pathogenassociated molecular patterns (PAMPs) that act as danger signals. VNPs administered via various routes (including subcutaneously and intramascular) drain efficiently to lymph nodes and activate immune cells upon recognition by pattern recognition receptors. VNP-based vaccines also facilitate antigen cross-presentation, which is crucial for major histocompatibility complex class I (MHC-I) presentation of extracellular antigens to trigger a robust cytotoxic T cell response. For example, plant VNPs, including papaya mosaic virus, TMV and potato virus X, can generate robust cellular responses against fused epitopes 87 . The potency of the immunostimulatory properties of VNPs has been demonstrated in an in situ cowpea mosaic virus (CPMV) vaccine, showing remarkable efficacy in animal models of melanoma, glioma, breast, colon and ovarian cancer [88] [89] [90] [91] [92] . Here, the VNPs are administered directly into the tumour to stimulate innate immune cells within the tumour microenvironment, priming tumour cell killing and antigen processing, which results in systemic antitumour immunity. In contrast to oncolytic viral tumour therapy, pre-existing immunity does not decrease the effectiveness of the immune response induced by the VNPs 89 . Instead, antibody recognition increases opsonization of CPMV, thereby improving the recognition of the virus by innate immune cells, which are its natural targets. The CPMV cancer immunotherapy has also shown efficacy in companion animals with spontaneous tumours 93 . Therefore, VNPs are excellent epitope delivery platforms for antigens ( fig. 2d) and adjuvants for vaccine and immunotherapy applications 94 . The current preclinical development pipeline for VNP-based vaccines includes infectious, cardiovascular and autoimmune diseases as well as substance abuse 95 . Plant VNP vaccine platform technologies also hold promise for pandemic or epidemic vaccines 96 -owing to their high thermal stability they would not be subject to cold chain distribution and/or could be produced in the region for the region through molecular farming.

The successful vaccination of entire populations in low-resource areas is an arduous task, which will require addressing distribution challenges in relation to cold chain failures and the lack of trained health-care providers with vaccine experience 97 .

The majority of traditional (live and inactivated) vaccines approved for use are advised to be distributed through the cold chain at 2-8 °C for optimal activity. The cold chain is a temperature-controlled supply chain of the people, equipment and protocols used in the transportation, storage and handling of vaccines from manufacturer to patient (fig. 3 ). When disrupted, vaccine denaturation can lead to less effective vaccines with greater side effects. The 'last mile' vaccine distribution, describing the allocation of vaccines from national distribution centres to regional facilities and patients, is especially challenging, as evidenced in the SARS-CoV-2 vaccine rollout. The World Health Organization (WHO) reported that in 2011, 2.8 million vaccine doses were lost owing to cold chain disruptions in five countries surveyed. Therefore, in 2012, the WHO expressed a preference for vaccines that are heat-and freeze-stable for extended periods above 8 °C, as a part of the controlled temperature chain 98 .

Cold chain disruptions can occur from a variety of sources. Vaccines can be exposed to extended periods of heating owing to electricity and power outages, equipment failure, limited ice supplies, and transportation and delivery delays 99 b | Encapsidation of molecular payloads within the cowpea chlorotic mosaic virus (CCMV) through dis-assembly and re-assembly of coat proteins following changes in the solvent conditions. c | Delivery of molecular payloads with tobacco mosaic virus (TMV) using internal glutamate (Glu) or external tyrosine (Tyr) residues. Therapeutic payloads can be loaded into the interior of the TMV or conjugated to the exterior surface of TMV. d | Epitope delivery using plant viral nanoparticles (VNPs). Vaccination with VNPs leads to intracellular processing of the antigen or genomic material encoding the antigen. The antigen is then displayed on the cell surface, leading to the activation of CD4 + and CD8 + T cells. CD4 + T cells go on to activate memory B cells, leading to immune memory against future infections. APC, antigen-presenting cell; BCR, B cell receptor; MHC, major histocompatibility complex; VLP, virus-like particle. The plant VNPs were drawn using UCSF Chimera (CPMV PDB ID: 1NY7; CCMV PDB ID: 1CWP; TMV PDB ID: 2TMV), and parts of fig. 3d were made using https://smart.servier.com/.

www.nature.com/natrevmats compromised by vaccine freezing owing to ice build-up in refrigerators or improper ice conditioning 98 .

Overcoming immunization challenges requires collaboration between multiple parties involved in the vaccine supply chain. First, a better understanding of the impact of heat or freeze exposure on vaccine stability is needed. The WHO further demands that all vaccines purchased by the United Nations Children's Fund must have vaccine vial monitors 100 that measure cumulative heat exposure and signal whether the vaccine should be discarded in case of cold chain disruptions. Vaccine vial monitors are cheap and indispensable; however, they can fail; for example, an oral polio vaccine with a 48-hour controlled temperature chain (indicated by the manufacturer) maintained viable potency for up to 86.9 hours above 8 °C, even though the vaccine vial monitor indicated it had reached its end point 101 . In addition, it is important that health-care professionals are trained to read and interpret vaccine vial monitor data and in handling procedures, such as preventing sunlight exposure, which can lead to false positives and premature vaccine discards 102 . Similarly, freeze indicators and shake-tests for freeze-induced protein aggregation can measure potency, in cases when freezing temperatures are a concern 98 . Thermostable liquid and dry vaccine formulations can further address cold chain-related challenges. Liquid vaccines can benefit from high-throughput optimization of formulation properties, such as buffer type, pH and ionic strength, to improve stability. Dry vaccines can be more thermostable but must be reconstituted before use. Reconstitution is limited by large product volumes, logistical concerns, and potential sources of error and contaminants. Dry vaccines need simple-to-use reconstitution systems or strategies to bypass the need for reconstitution, for example, by applying aerosols, dry powder jet injection, microneedle patches or biodegradable implants 103 . Moreover, the ability to withstand temporary storage or transport without refrigeration or ice would help mitigate cold chain disruptions, particularly in areas where health workers travel by foot 104 or where there is a lack of cold boxes 102 .

Health-care workers connect every step of the vaccine supply chain and, thus, require adequate training for each vaccine, including reconstitution methods, handling of the cold chain and controlled-temperature chain, and reading of vaccine vial monitors. Negligent handling may result in wasted vaccines or the delivery of ineffective vaccines 103 . Therefore, easy-to-use vaccines that require less training may reduce human error, for example, single-use or self-administered systems. UniJect, which is a pre-filled single-use system 105 , is easy to use, activated by simply pushing the needle through a membrane and into the drug reservoir, and its valve ensures that the vaccine can only be used once by preventing the needle from retracting. The UniJect system has also been reported to be less painful and anxiety-inducing for patients 105 .

The definition of successful vaccine implementation could further be redefined from cost per dose to cost per dose delivered, to reflect the true cost of introducing a new vaccine 104 . A higher cost per dose would probably be accepted for a more stable vaccine, because of reduced wastage, lower storage and handling costs, better efficacy and protection, and easier management, as compared with less-stable vaccines, making it more cost-effective overall. For example, single-use systems, such as UniJect, add $US0.15-0.30 to the cost per dose, compared with traditional single-use syringes; however, the 20% wastage rate for multi-dose vials and the fact that UniJect can be administered at home lead to a decrease in cost per dose delivered, from $US7.19 to $US6.57 in the case of tetanus 106 . Therefore, dose-sparing technologies in vaccine manufacturing, deployment and administration can have a substantial impact on immunization success and costs.

Plants can be used to produce vaccines at small scale and low cost in regions where vaccines are most needed, particularly in areas where it may be difficult to set up cGMP-level bacterial and mammalian cell culture systems. In addition, contaminants from plant molecular farming are not as harmful as endotoxins produced in bacterial expression 61 . Moving vaccine manufacturing on-site would also reduce cold chain requirements, because long-distance shipping would not be needed; this has been especially highlighted during the SARS-CoV-2 vaccine rollout. In 67 low-income countries, an estimated 90% of the population may not gain access to any SARS-CoV-2 vaccine in 2021 (ref. 107 ). Therefore, plant molecular farming could reduce vaccine inequity and immunization costs 108 . Furthermore, production of vaccines by plant molecular farming does not require extensive space; for example, it was calculated that Italy could reach a 60% vaccination rate with 12,500 square metres of greenhouses 45 . Moreover, molecular farming is easily scalable, compared with fermentation systems, which must be adapted and optimized for scale-up, and which require costly bioreactors. 

By contrast, each plant is a bioreactor, and scale-up is simply achieved by growing more plants. Plant molecular farming is particularly useful for producing plant viruses as nanocarriers for vaccines. Plant VNPs are very stable and can withstand temperatures outside cold chain requirements; for example, CPMV withstands temperatures of 37 °C for 46 days 109 and 60 °C for up to 1 hour 110 . Thermostability is especially important in areas in which resources for adequate cold chain distribution of vaccines may be limited. Furthermore, plant viruses, owing to their intrinsic stability, can withstand the processing and manufacturing steps of vaccine packaging into new administration technologies, such as microneedles 96 . VNPs do not only act as carriers, but also as adjuvants, reducing the number of vaccine components. Moreover, the simplicity of VNP-based vaccines can improve health-care worker compliance and reduce the need for training in vaccine administration.

Administration of vaccines with hypodermic needles, which is currently the most frequently used administration technology, has several drawbacks. For example, blood-borne pathogens can easily be spread by needle reuse or mishandling 111 . Moreover, patients may be apprehensive about needles 112 . Vaccines delivered by hypodermic needles also rely on liquid formulations for injections, which require a cold chain 113 .

To overcome these obstacles, vaccines can be encapsulated in polymeric materials. Proteins in the solid state embedded within a polymer matrix further improve the thermal stability of the vaccine, thereby decreasing strict adherence to the cold chain 114 . Polymeric materials could be used in new vaccine delivery platforms that could supplant hypodermic needles, improving patient compliance and reducing the unintended spread of blood-borne pathogens. Next-generation polymeric delivery platforms that are safe, effective and self-administered could thus greatly strengthen concerted vaccination efforts.

Considerable research has been devoted to the development of biocompatible and biodegradable polymeric materials for vaccines 115 (Table 3 ). These materials can be of synthetic or natural origin, and processing and manufacturing requirements can differ for each polymer, which may restrict the use of biological components. For example, inactivated or live attenuated vaccines can denature at high temperatures, which restricts the processing conditions (some processes require temperatures above 70 °C) required to encapsulate these vaccines in polymeric materials 113 . By contrast, VLPs and VNPs are chemo-and thermostable, enabling a broader array of device manufacturing conditions 116 . Fabricated by plant molecular farming, VLPs and VNPs can be produced at large scales for material integration at lower cost, as compared with conventional inactivated or live attenuated vaccines 108 .

Polymeric materials, developed for next-generation vaccine administration, generally act as delivery vehicles, allowing the controlled release of antigen and adjuvant over weeks to years, depending on the type of material. The antigen release rate can be controlled by tuning the material properties. The presence of degradable bonds in the polymer's backbone and its hydrophilicity, molecular weight and crystallinity influence the degradation rate of both synthetic and natural polymers. For example, to enable instantaneous burst release, antigens can be encapsulated in rapidly dissolving water-soluble polymers, such as polyvinylpyrrolidone (PVP), which can be processed into microneedles for intradermal vaccine delivery 117 . A slow and sustained release can be achieved by choosing slowly degrading polymers, such as poly(lactic-co-glycolic acid) (PLGA) 118 . Increasing the window of antigen delivery can further improve the efficacy of vaccines 119, 120 . By combining burst and slowrelease strategies, single-dose regimens can be designed that mimic the multi-dose prime-boost regimen of conventional vaccines 121 ; for example, a vaccine could be encapsulated in both a burst-release polymer and a slow-release polymer, which can then be simultaneously administered.

Delivery of adjuvants is key for vaccines. Some subunit vaccines, such as VLPs or recombinant VLPs and VNPs, which deliver subunit antigens, may not require additional adjuvants because the VLP or VNP itself acts as the adjuvant through recognition and activation of pattern recognition receptors 122 . However, for moderately or poorly immunogenic antigens, adjuvants need to be added to the formulation. The most frequently used adjuvants are aluminium-based salts (alum) 113 , which serve both as a delivery vehicle by adsorbing antigen to the surface and as an immunostimulator by inducing pro-inflammatory signalling cascades 123 . Similarly, polymers such as alginate, hyaluronic acid and PLGA can act as both delivery vehicle and adjuvant owing to their natural inflammatory properties 124 . Further activation of innate immunity can be achieved through co-delivery of Toll-like receptor (TLR) ligands, such as CpG-oligodeoxynucleotide or monophosphoryl lipid A. Here, materials design is crucial, because a growing body of data suggests that co-delivery of adjuvant and antigen to the same antigen-presenting cell is important to enhance vaccine efficacy and to increase safety by lowering the likelihood of an uncontrolled and unspecific systemic immune response 125 .

As an alternative to subcutaneous injection with hypodermic needles, other routes of administration have been explored, using different device designs and fabrication, which have a considerable effect on immunostimulation. Here, we discuss two delivery constructs for vaccine self-administration: nano-and microparticle formulations, and microneedle patches. Using these devices, vaccines can be self-administered by intradermal, intranasal or oral administration ( fig. 4 ).

Vaccines can be encapsulated in polymeric nano-and microparticles. For example, polyester-based microparticles, such as PLGA microparticles, can be fabricated starting with an initial water-inoil dispersion of polymer and antigen, followed by an www.nature.com/natrevmats additional emulsion and solvent removal step, polymer phase separation or spray drying 126 . By contrast, polyanhydrides require completely anhydrous conditions (solid-oil-oil dispersions) to prevent premature polymer hydrolysis 127 . Antigens can also be encapsulated in ionic polymers, such as polyphosphazenes and polysaccharides, by crosslinking of the polymers through the addition of oppositely charged multivalent ions in aqueous and ambient conditions. However, these fabrication techniques have several drawbacks, which can limit their use for certain biologics. For example, water-in-oil dispersion has low encapsulation efficiencies, which may limit its use for expensive and difficultto-produce biologics 128 . Importantly, the fabrication process can affect antigen stability 129 ; for example, antigens can degrade or unfold owing to interactions at the aqueous-organic interface or to high shear forces during emulsification 130 . Nano-and microparticles are often used in selfadministered intranasal vaccines. Here, antigens are encapsulated within nano-or microparticles, usually made of poly(lactic acid) or PLGA, and administered as a spray or aerosol, ideally targeting immune cells that reside in the nasal-associated lymphoid tissue of the upper respiratory tract 131 . However, following intranasal administration, the mucociliary clearance mechanism may clear the deposited vaccine particles, with a half-life of around 20 minutes 132 . To prevent rapid clearance, the vaccines can be formulated with mucoadhesive polymers, such as chitosan, which can translocate across the nasal mucosal barrier and prolong the residence time to hours or days to improve the immune response 133 .

Microneedles are microscale projections, usually 50 to 900 μm in height, which can pierce the upper layers of the skin and facilitate transdermal delivery of vaccines 134 . Microneedles do not puncture deep enough to activate the nociceptors within the skin and are therefore considered painless. Microneedles can achieve greater immunological responses, compared with traditional routes of administration, such as intramuscular or subcutaneous injection, owing to the abundant immune cell population in the upper layers of the skin, including the Langerhans cells in the epidermis and the dendritic cells in the dermis 135, 136 . They can also be fabricated to deliver a range of biological vaccines, each polymer was then calculated from the total and graphed. c | Number of patent applications for microneedle, microparticle and nanoparticle vaccine delivery technologies. The terms 'microneedle', 'microparticle' and 'nanoparticle' were searched on www.uspto.gov, and the total number of publications for each search term was graphed with respect to publication date. d | Routes of administration for vaccine delivery proposed by patent applications. The number of patents mentioning the respective route of administration as well as the term "vaccine" were counted on www.uspto. gov and totalled. The respective percentage of each route of administration was then calculated from the total and graphed.

www.nature.com/natrevmats including inactivated and live attenuated viruses, VLPs and VNPs, protein subunits and DNA 137 . Importantly, encapsulation in microneeedle patches increases the thermostability of these biologics, which is particularly important for vaccination in regions without proper cold chain infrastructure. Therefore, microneedles are perhaps the most promising device for widespread vaccine distribution and self-administration.

Coated and dissolving microneedles have also been developed. Coated microneedles are designed by coating the surface of microneedles with antigen by dry-coating 138 or layer-by-layer electrostatic deposition 139 . Upon skin puncture, the coated antigen is immediately released to elicit an immunological response. For dry-coating, a stainless steel or silicon microneedle is dip-coated or dry-sprayed with a mixed solution of antigen and carboxymethylcellulose 140 , polysaccharides 141 or synthetic polymers 142 . A disadvantage of this method is its limited loading capacity 134 . However, loading can be increased by layer-by-layer electrostatic deposition; here, layers of oppositely charged polymers and proteins or nucleic acids are deposited in an alternating fashion 139 .

For the fabrication of dissolving microneedles, antigen is encapsulated within the microneedle tips, either in the bulk material or in microparticles. Upon insertion into the upper layers of the skin, the microneedles dissolve at rates dependent on the materials used 143 . Each material has advantages and disadvantages (Table 3) ; for example, PVP 117 rapidly dissolves upon contact with the interstitial fluid, which decreases the application time of the microneedles, but requires high doses owing to fast clearance rates. Alternatively, chitosan biodegrades slowly, thereby acting as a sustained-release depot. Chitosan microneedles have been shown to induce a more potent and long-lasting immune response compared with conventional intramuscular injection or injection with alum 121, 144 . Dissolving microneedles are usually manufactured by micromoulding 145 . Here, a mould is first filled with a polymer solution containing the antigen and then placed under vacuum or centrifuged to draw the solution into microcavities. The device is then allowed to dry and harden to form robust microneedle arrays. Water-soluble polymers, such as carboxymethyl cellulose and PVA, manufactured into microneedles under mild conditions, can protect encapsulated antigens from degradation 146, 147 . Alternatively, dissolving microneedles can be fabricated by ultraviolet photo-polymerization of PVP within the mould 117 or by high-temperature moulding 148 ; however, these processes can cause antigen degradation, because they require harsher conditions than solvent-based moulding.

Microneedles with plant-produced antigens have already been shown to be effective. For example, a recombinant influenza VLP vaccine (along with a glucopyranosyl lipid adjuvant) administered by the NanoPass MicroJet microneedle, produced equal levels of haemagglutinin inhibition titres and seroprotection in humans, compared with intramuscular injection 149 . In ferrets, the microneedle formulation led to 100% survival against a H5N1 challenge. Microneedle delivery also enables in situ vaccination; for example, microneedle-delivered CPMV showed greater potency in a mouse model of melanoma compared with intratumoral injection of CPMV, resulting in slower tumour growth and improved overall survival 150 .

The use of biologics in pharmaceutical applications will continue to grow as expression and purification technologies develop and mature. Plant molecular farming, in particular, is poised to make an impact on an array of applications, and new methodologies, such as the cookie technique, will continue to drive forward its use. Plant molecular farming is currently applied mainly in niche applications; however, recent developments and milestones, such as the production of millions of influenza vaccine doses in record time, has put a spotlight on this manufacturing platform 45 . Following such successes, it is likely that molecular farming will gain in market share. We have just witnessed the worldwide efforts by laboratories and industry in pivoting their particular platforms and tools towards making vaccines, therapeutics or reagents for the ongoing COVID-19 pandemic or the Zika and Ebola epidemics 11, 151 . Plant molecular farming requires less sophisticated infrastructure than does conventional vaccine production, and thus could be locally deployed in each region, therefore addressing vaccine rollout challenges. Moreover, plant molecular farming could enable the production of vaccines, therapeutics or reagents in space, either on a space station, or during months-long missions to Mars or other extraterrestrial destinations 152 . The first grants supporting this technology have already been issued, for example, the NASAfunded use of transgenic lettuce and potato leaves to produce growth factors and hormones for astronauts to combat osteoporosis and other spaceflight-related health issues 152 .

However, expression levels in plant molecular farming must improve to levels similar to those achieved in mammalian or bacterial systems. Expression in bacterial systems was first achieved in the 1970s, ten years before expression in plants 153 . This gap means that plant molecular farming lags behind other expression systems in terms of expression efficiency, which will be addressed by more efficient plant systems that can produce proteins at larger yields. In addition, downstream processing and purification of biologics need to improve, which remains challenging owing to the complexity of plant cells and tissues (plants produce 30% more solid debris than other expression systems and contain many contaminants, such as phenolics, which interfere with purification). The FDA Critical Path Report states that downstream processes were one of the key reasons that plant-made proteins routinely failed to transition into the clinic or industry 154 . However, new methods, such as using acqueous two-phase partitioning systems, enzymatic hydrolysis, ultrasound, microwaves, pulsed electric fields, high-voltage electric discharge, ohmic heating, vacuum, subcritical and supercritical fluids, and hydrotropic and deep eutectic solvents are being developed to improve downstream processing of plant material 155, 156 .

Manufacturing of biologics by plant molecular farming is currently performed mainly at small scales NATURE REvIEwS | Materials by academic research laboratories and mid-sized pharmaceutical companies, at a lower cost than traditional fermentation-based expression systems (up to ten times and a hundred times lower than the production costs in E. coli and CHO cells, respectively) 157 . Once plant molecular farming reaches agricultural crop scales, the margins are expected to widen even further. The lower costs will help to offset the expensive costs of everyday laboratory research. Thus, molecular farming has the potential to reduce the price of recombinant therapeutics to levels similar to those of everyday over-the-counter medications. Molecular farming could also play a key part in producing biosimilars (biologics that are not identical to the original product, but are equally efficacious) to fabricate cheap pharmaceuticals or biological test reagents for all populations. In addition, decreasing the price of medications would also greatly reduce financial strains on the health-care system. For example, the monoclonal antibodies used in the alleviation of rheumatoid arthritis are currently unaffordable outside health-care systems in developed regions, although the majority of sufferers remain in underdeveloped regions.

Future vaccines should be engineered to be free of cold chain restrictions, for example, by producing orally dosed vaccines and therapeutics in plants. Although the 1990s dream of simply 'eating your vaccines' is unattainable (mainly owing to low yield of active ingredient and dose control), transgenic plants consumed by humans, such as potatoes, tomatoes and corn, can be used to not only deliver partially purified and quantified antigen, but also to protect the antigen within a heat-stable environment 158 . The rigid plant cell wall can protect antigens from degradation within the harsh environment of the gastrointestinal system, while allowing antigen delivery 159 . The use of orally dosed vaccines can help reduce cold chain requirements and obviate the need for antigen purification and downstream processing 62 . The amount of land required to vaccinate entire countries by orally dosed vaccines would also be minimal (for example, all of China could be vaccinated with only 40 hectares of land) 62 .

Cold chain restrictions could also be mitigated by using new delivery agents, such as plant-made VNPs, that are intrinsically thermostable over a range of temperatures and pH levels, allowing their use in microneedle patches (which require high-temperature processing methods 110 ), and in oral vaccines (avoiding denaturation by the acidic gastrointestinal environment 160 ). Finally, new formulation chemistries and next-generation materials are anticipated to enhance formulation stability and improve delivery techniques. For example, the biomineralization of viral vaccines generates a mineral exterior, which improves the thermostability of the viral antigen 161 . Furthermore, new combinations of excipients can further extend the half-life of vaccines 162 . Finally, the formulation of biologics in microneedle patches and/or slow-release formulations has tremendous potential for the self-administration of medication.

Thus, platform technologies to produce biologics from living systems continue to develop as new technologies become available, and next-generation nanotechnology and materials science have opened up opportunities in formulation chemistry and the administration of pharmaceuticals.

Published online xx xx xxxx

Beyond traditional pharmacology: new tools and approaches

Increased MSX level improves biological productivity and production stability in multiple recombinant GS CHO cell lines. Eng

Biologics and biosimilars: what, why and how? ESMO Open

Simply put: vaccination saves lives

The contribution of vaccination to global health: past, present and future

Return on investment from childhood immunization in low-and middle-income countries

The expression of a nopaline synthase -human growth hormone chimaeric gene in transformed tobacco and sunflower callus tissue

Efficacy, immunogenicity, and safety of a plant-derived, quadrivalent, virus-like particle influenza vaccine in adults (18-64 years) and older adults (≥65 years): two multicentre, randomised phase 3 trials

brief: Taliglucerase (Elelyso) for Gaucher disease

Plant molecular farming of virus-like nanoparticles as vaccines and reagents

COVID-19 vaccine frontrunners and their nanotechnology design

The COVID-19 vaccine race: challenges and opportunities in vaccine formulation

History of vaccination

The early use of Pasteur's rabies vaccine in the United States

Cultivation of the Lansing strain of poliomyelitis virus in cultures of various human embryonic tissues

Synthesis and assembly of hepatitis B virus surface antigen particles in yeast

COVID-19 vaccine: a comprehensive status report

Vaccines for the 21st century

Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices

The quest for a truly universal influenza vaccine

Vaccination with human papillomavirus pseudovirus-encapsidated plasmids targeted to skin using microneedles

A scalable manufacturing approach to single dose vaccination against HPV

Why don't we have a vaccine against autoimmune diseases? -a review

The ways of isolating neoantigenspecific T cells

Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK

Cell factories for insulin production

Comparison of immunogenicity of two yeast-derived recombinant hepatitis B vaccines

A brief reminder of systems of production and chromatography-based recovery of recombinant protein biopharmaceuticals

Recombinant protein production in bacterial hosts

Microbial factories for recombinant pharmaceuticals

Strategies for achieving high-level expression of genes in Escherichia coli

Recent developments in bioprocessing of recombinant proteins: expression hosts and process development

CHO cells in biotechnology for production of recombinant proteins: current state and further potential

Human cell lines for biopharmaceutical manufacturing: history, status, and future perspectives

Production platforms for biotherapeutic glycoproteins. Occurrence, impact, and challenges of non-human sialylation

Posttranslational modifications and the immunogenicity of biotherapeutics

Insect cell culture for industrial production of recombinant proteins

The baculovirus expression vector system: a commercial manufacturing platform for viral vaccines and gene therapy vectors

Influenza vaccines: the potential benefits of cell-culture isolation and manufacturing

Relative effectiveness of cellcultured and egg-based influenza vaccines among elderly persons in the United States

A risk-assessment model to rate the occurrence and relevance of adventitious agents in the production of influenza vaccines

This paper gives an overview of molecular farming innovations for vaccines in both humans and animals

An integral approach towards a practical application for a plant-made monoclonal antibody in vaccine purification

Farming of plant-based veterinary vaccines and their applications for disease prevention in animals

Plant molecular farming as a strategy against COVID-19 -the Italian perspective

This paper highlights some of the drugs and vaccines produced through molecular farming in the fight against COVID-19

Phase 1 trial of a candidate recombinant virus-like particle vaccine for Covid-19 disease produced in plants

SARS-CoV-2 vaccines strategies: a comprehensive review of phase 3 candidates. npj Vaccines

Transgene expression in microalgae -from tools to applications

The algal chloroplast as a synthetic biology platform for production of therapeutic proteins

Green biologics: the algal chloroplast as a platform for making biopharmaceuticals

Advantages of therapeutic protein production in the aquatic plant Lemna

Moss-made pharmaceuticals: from bench to bedside

Potential of plants to produce recombinant protein products

This paper provides a broad overview of the current industry of plant-produced biologics, highlighting the benefits compared with other expression systems as well as the challenges associated with plant molecular farming

Plant-produced vaccines: promise and reality

Plant molecular farming: much more than medicines

Development of systems for the production of plant-derived biopharmaceuticals

Production of glucocerebrosidase with terminal mannose glycans for enzyme replacement therapy of Gaucher's disease using a plant cell system

Preclinical and clinical development of plant-made virus-like particle vaccine against avian H5N1 influenza

Co-expression of human calreticulin significantly improves the production of HIV gp140 and other viral glycoproteins in plants

Comparative evaluation of recombinant protein production in different biofactories: the green perspective

A review on edible vaccines and their prospects. Braz

Immunogenicity of plant-produced human papillomavirus (HPV) virus-like particles (VLPs). Vaccines

A plant-produced vaccine protects mice against lethal West Nile virus infection without enhancing Zika or dengue virus infectivity

Plant-made dengue virus-like particles produced by co-expression of structural and non-structural proteins induce a humoral immune response in mice

Production of human papillomavirus pseudovirions in plants and their use in pseudovirion-based neutralisation assays in mammalian cells

In planta production of flock house virus transencapsidated RNA and its potential use as a vaccine

On the way to commercializing plant cell culture platform for biopharmaceuticals: present status and prospect

Plant cell packs: a scalable platform for recombinant protein production and metabolic engineering

Robot cookies -plant cell packs as an automated high-throughput screening platform based on transient expression

The role of novel immunotherapies in non-Hodgkin lymphoma

Tobacco derived cancer vaccines for non-Hodgkin's lymphoma: perspectives and progress

Clinical safety and immunogenicity of tumor-targeted, plant-made Id-KLH conjugate vaccines for follicular lymphoma

Plant-made vaccines and reagents for the One Health initiative

Plant-produced Crimean-Congo haemorrhagic fever virus nucleoprotein for use in indirect ELISA

Expression of Rift Valley fever virus N-protein in Nicotiana benthamiana for use as a diagnostic antigen

Calreticulin co-expression supports high level production of a recombinant SARS-CoV-2 spike mimetic in Nicotiana benthamiana

Synthetic plant virology for nanobiotechnology and nanomedicine

Plant viruses and bacteriophages for drug delivery in medicine and biotechnology

Future of cancer immunotherapy using plant virus-based nanoparticles

Biomimetic virus-like particles as severe acute respiratory syndrome coronavirus 2 diagnostic tools

Viral nanoparticles for drug delivery, imaging, immunotherapy, and theranostic applications

This paper provides an in-depth overview of viral nanoparticles (with a focus on plant viral nanoparticles) used in drug delivery, imaging, immunotherapy and theranostics

Engineering a plant viral coat protein for in vitro hybrid self-assembly of CO 2 -capturing catalytic nanofilaments

Physalis mottle virus-like nanoparticles for targeted cancer imaging

Delivery of pesticides to plant parasitic nematodes using tobacco mild green mosaic virus as a nanocarrier

Viral contamination in biologic manufacture and implications for emerging therapies

Plant viruses as nanoparticle-based vaccines and adjuvants

Plant virus-like particle in situ vaccine for intracranial glioma immunotherapy

Antibody response against cowpea mosaic viral nanoparticles improves in situ vaccine efficacy in ovarian cancer

In situ vaccination with cowpea vs tobacco mosaic virus against melanoma

Cowpea mosaic virus immunotherapy combined with cyclophosphamide reduces breast cancer tumor burden and inhibits lung metastasis

In situ vaccination with cowpea mosaic virus nanoparticles suppresses metastatic cancer

Treatment of canine oral melanoma with nanotechnology-based immunotherapy and radiation

Plant virus particles with various shapes as potential adjuvants

Plant viruses and bacteriophagebased reagents for diagnosis and therapy

Trivalent subunit vaccine candidates for COVID-19 and their delivery devices

The future of routine immunization in the developing world: challenges and opportunities

Can thermostable vaccines help address cold-chain challenges? Results from stakeholder interviews in six low-and middle-income countries

The imperative for stronger vaccine supply and logistics systems

Vaccine vial monitor availability and use in low-and middle-income countries: a systematic review

Using oral polio vaccine beyond the cold chain: a feasibility study conducted during the national immunization campaign in Mali

Assessing the potency of oral polio vaccine kept outside of the cold chain during a national immunization campaign in Chad

Opportunities and challenges of developing thermostable vaccines

A cost comparison of introducing and delivering pneumococcal, rotavirus and human papillomavirus vaccines in Rwanda

Uniject as a delivery system for the once-a-month injectable contraceptive Cyclofem in Brazil

Home delivery of heat-stable vaccines in Indonesia: outreach immunization with a prefilled, single-use injection device

Covid-19: many poor countries will see almost no vaccine next year, aid groups warn

This paper highlights how plant molecular farming could especially benefit and improve the health of citizens in low-to middle

Development of a non-infectious encapsidated positive control RNA for molecular assays to detect foot-and-mouth disease virus

Icosahedral virus particles as addressable nanoscale building blocks

One needle, one syringe, only one time? A survey of physician and nurse knowledge, attitudes, and practices around injection safety

Fear of injections in young adults: prevalence and associations

Vaccine instability in the cold chain: mechanisms, analysis and formulation strategies

The role of moisture in protein stability

This paper provides an overview of different polymers and their respective contributions to the biomedical fields of drug delivery and tissue engineering

Biodegradable viral nanoparticle/ polymer implants prepared via melt-processing

Dissolving polymer microneedle patches for influenza vaccination

Poly lactic-co-glycolic acid (PLGA) as biodegradable controlled drug delivery carrier

Sustained antigen availability during germinal center initiation enhances antibody responses to vaccination

Extending antigen release from particulate vaccines results in enhanced antitumor immune response

Next generation vaccines: single-dose encapsulated vaccines for improved global immunisation coverage and efficacy

Interaction of viral capsid-derived virus-like particles (VLPs) with the innate immune system

New horizons in adjuvants for vaccine development

Materials for immunotherapy

Controlled drug delivery by biodegradable poly(ester) devices: different preparative approaches

Polyanhydrides: an overview

The mechanism of PLA microparticle formation by water-in-oil-in-water solvent evaporation method

Protein instability in poly(lactic-co-glycolic acid) microparticles

Protein instability toward organic solvent/ water emulsification: implications for protein microencapsulation into microspheres

Chitosan as a novel nasal delivery system for vaccines

Evaluation of the clearance characteristics of bioadhesive systems in humans

Rational design of nasal vaccines

Recent advances of microneedles for biomedical applications: drug delivery and beyond

This Review highlights recent developments in microneedle drug delivery applications in the fields of therapeutics, vaccines, diagnosis and cosmetics, and compares and contrasts the different types of microneedles

Skin immune sentinels in health and disease

Microneedles: a new generation vaccine delivery system

Microneedle patches as drug and vaccine delivery platform

Formulation and coating of microneedles with inactivated influenza virus to improve vaccine stability and immunogenicity

Releasable layer-by-layer assembly of stabilized lipid nanocapsules on microneedles for enhanced transcutaneous vaccine delivery

Coated microneedles for transdermal delivery

Stability of whole inactivated influenza virus vaccine during coating onto metal microneedles

Intradermal immunization using coated microneedles containing an immunoadjuvant. Vaccine

Microneedle-based drug delivery systems: microfabrication, drug delivery, and safety

Fully embeddable chitosan microneedles as a sustained release depot for intradermal vaccination

Dissolving and biodegradable microneedle technologies for transdermal sustained delivery of drug and vaccine

Langerin negative dendritic cells promote potent CD8 + T-cell priming by skin delivery of live adenovirus vaccine microneedle arrays

A microneedle patch containing measles vaccine is immunogenic in non-human primates

Polymer microneedles for controlled-release drug delivery

The adjuvant GLA-AF enhances human intradermal vaccine responses

Active microneedle administration of plant virus nanoparticles for cancer in situ vaccination improves immunotherapeutic efficacy

Virus-based pharmaceutical production in plants: an opportunity to reduce health problems in Africa

Molecular pharming to support human life on the Moon, Mars, and beyond

A history of recombinant protein technology in small molecule drug discovery

Viral vectors for production of recombinant proteins in plants

Development of an aqueous two-phase partitioning system for fractionating therapeutic proteins from tobacco extract

Recent advances in the recovery techniques of plant-based proteins from agro-industrial by-products

Towards molecular farming in the future: moving from diagnostic protein and antibody production in microbes to plants

Medical molecular farming: production of antibodies, biopharmaceuticals and edible vaccines in plants

Recent Trends in Biotechnology and Therapeutic Applications of Medicinal Plants

Stability of plant virus-based nanocarriers in gastrointestinal fluids

Rational design of thermostable vaccines by engineered peptide-induced virus self-biomineralization under physiological conditions

Novel formulations enhance the thermal stability of live-attenuated flavivirus vaccines

Measles, mumps, and rubella virus vaccine (M-M-R TM II): a review of 32 years of clinical and postmarketing experience

Prevention of hepatitis A by Havrix: a review

Safety, tolerability and immunogenicity of a recombinant hepatitis B vaccine manufactured by a modified process in healthy young adults

Human papillomavirus vaccines: an updated review

Recombinant protein vaccines, a proven approach against coronavirus pandemics

Durability of response to VGX-3100 treatment of HPV16/18 positive cervical HSIL

Development of pandemic vaccines: ERVEBO case study

First human efficacy study of a plant-derived influenza vaccine

Transformation of HBsAg (hepatitis B surface antigen) gene into tomato mediated by Agrobacterium tumefaciens

Expression of Escherichia coli heat-labile enterotoxin b subunit (LTB) in carrot (Daucus carota L.)

Oral immunization with rotavirus VP7 expressed in transgenic potatoes induced high titers of mucosal neutralizing IgA

Expression of an immunogenic Ebola immune complex in Nicotiana benthamiana

High expression of foot-and-mouth disease virus structural protein VP1 in tobacco chloroplasts

A Plant-Produced Pfs25 VLP malaria vaccine candidate induces persistent transmission blocking antibodies against Plasmodium falciparum in immunized mice

Bioprocessing of plant-derived virus-like particles of Norwalk virus capsid protein under current good manufacture practice regulations

Expression of dengue virus E glycoprotein domain III in non-nicotine transgenic tobacco plants

High accumulation in tobacco seeds of hemagglutinin antigen from avian (H5N1) influenza

Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaques

Plant-made vaccines in support of the millennium development goals

Preclinical and first-in-human evaluation of PRX-105, a PEGylated, plant-derived, recombinant human acetylcholinesterase-R

Recombinant human lactoferrin treatment for global health issues: iron deficiency and acute diarrhea

Monoclonal antibodies B38 and H4 produced in Nicotiana benthamiana neutralize SARS-CoV-2 in vitro

Rapid production of SARS-CoV-2 receptor binding domain (RBD) and spike specific monoclonal antibody CR3022 in Nicotiana benthamiana

Large-scale production of pharmaceutical proteins in plant cell culture -the protalix experience

Expression of the rabies virus nucleoprotein in plants at high-levels and evaluation of immune responses in mice

The return of a forgotten polymer -polycaprolactone in the 21st century

Biocompatibility, biodegradation and excretion of polylactic acid (PLA) in medical implants and theranostic systems

Polyphosphazenes: multifunctional, biodegradable vehicles for drug and gene delivery

Applications and emerging trends of hyaluronic acid in tissue engineering, as a dermal filler and in osteoarthritis treatment

Clinical pharmacokinetic considerations in the use of plasma expanders

Alginate: properties and biomedical applications

Fabrication of dissolving polymer microneedles for controlled drug encapsulation and delivery: bubble and pedestal microneedle designs

New Visions in Plant Science

Plant cell culture strategies for the production of natural products

Transient reprogramming of crop plants for agronomic performance

Floral dip: a simplified method for Agrobacterium-mediated transformation of Arabidopsis thaliana

Acknowledgements This work was funded in part by the following grants from the NIH (U01-CA218292, R01-CA224605, R01-CA253615

acknowledges research support from Medicago Inc. (Canada), the South African Medical Research Council and National Research Foundation, and the Poliomyelitis Research Foundation. E.C.K. was supported by the NIH T32EB005970 institutional training grant through the Clinician-Scientist Radiology

Nature Reviews Materials thanks Krishnendu Roy and the other, anonymous, reviewers for their contribution to the peer review of this work.

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

The world Health Organization (wHO): https://www.who. int/immunization/call-to-action_ipac-iscl.pdf